Pulmonary Medicine
Medically reviewed by Varun Halani, MD · August 13, 2026
Alpha-1 Antitrypsin Deficiency
An inherited condition in which the body doesn't produce enough functional alpha-1 antitrypsin, a protein that normally shields lung tissue from damage, leading to early-onset emphysema and, in some genotypes, liver disease.
In short
Alpha-1 antitrypsin deficiency is an inherited condition in which the body doesn't make enough of, or makes a dysfunctional form of, a protein that normally protects lung tissue from damage. This can lead to emphysema, often at a younger age and sometimes without a significant smoking history, and in some genotypes, to liver disease. A simple blood test is the usual first step in diagnosis, and current guidelines support at least one-time testing for anyone diagnosed with COPD.
Alpha-1 Antitrypsin Deficiency at a Glance
What It Is
An inherited condition in which the body doesn't produce enough functional alpha-1 antitrypsin, a protein that normally protects lung tissue from damage.
Main Effect
Reduced protection allows certain enzymes to damage lung tissue unchecked, often leading to emphysema at a younger age than typical, sometimes without significant smoking history.
Who's Tested
Anyone with COPD or emphysema at a younger age, without a significant smoking history, with a family history of AATD, or with unexplained liver disease.
How It's Diagnosed
A blood test measuring alpha-1 antitrypsin protein level, sometimes followed by genetic or protein-variant testing to characterize the specific variant.
Key Takeaways
- Alpha-1 antitrypsin deficiency is a genetic condition that leaves lung tissue less protected from everyday damage, often leading to emphysema.
- It's an under-recognized cause of COPD; testing guidelines generally recommend at least one-time testing for anyone diagnosed with COPD, not just those with an obvious "classic" presentation.
- Certain genotypes can also cause liver disease, since the abnormal protein can accumulate within liver cells rather than being released normally.
- A blood test measuring alpha-1 antitrypsin protein level is typically the first diagnostic step, with genetic or protein-variant testing used to characterize the specific variant when indicated.
- Because it's inherited, a confirmed diagnosis has implications for blood relatives, who may want to discuss testing with their own physician.
- Avoiding smoking is especially critical for people with alpha-1 antitrypsin deficiency, since it dramatically accelerates lung damage in this population.
Symptoms
Lung-Related Symptoms
- Shortness of breath with exertion, sometimes appearing in a person's 30s or 40s
- A persistent cough, at times productive of mucus
- Wheezing
- Reduced exercise tolerance
- Recurrent chest infections
Liver-Related Signs, in Some Genotypes
- Unexplained abnormal liver blood tests
- Yellowing of the skin or eyes (jaundice), at times in infancy
- Unexplained chronic liver disease, at any age
- Fatigue not otherwise explained
Common Questions When AATD Is Suspected
Should I be tested for alpha-1 antitrypsin deficiency if I have COPD?
Current testing guidelines generally recommend at least one-time testing for anyone diagnosed with COPD, reflecting how often this genetic cause is under-recognized. It's not limited to patients with an obviously "classic" presentation such as young age or no smoking history.
Does emphysema at a young age always mean AATD?
No, but it's a strong reason to test. Emphysema diagnosed at a younger age, especially without a significant smoking history, is one of the clinical patterns that specifically prompts alpha-1 antitrypsin deficiency testing.
If I'm diagnosed, should my family be tested too?
This is worth discussing with your physician. Because AATD is inherited, a confirmed diagnosis has implications for blood relatives, and parents, siblings, and children may want to discuss testing with their own physician.
Why Alpha-1 Antitrypsin Deficiency Causes Lung Damage
Inherited Gene Variants
Alpha-1 antitrypsin deficiency is caused by inherited variants in the gene responsible for producing the alpha-1 antitrypsin protein, passed from parents to children.
Reduced or Dysfunctional Protein
Depending on the specific combination of gene variants a person carries, the resulting alpha-1 antitrypsin protein may be produced in reduced amounts, may function poorly, or both.
Loss of Lung Protection
Alpha-1 antitrypsin normally neutralizes an enzyme that the body's own immune cells release during ordinary immune activity in the lungs. Without enough functional protein, that enzyme is left comparatively unchecked, gradually damaging the elastic tissue of the air sacs.
Accumulation in Liver Cells
In certain genotypes, the abnormal protein isn't released normally from the liver cells that produce it and instead accumulates there, which can lead to liver injury over time in some, though not all, affected individuals.
Risk Factors
- A family history of alpha-1 antitrypsin deficiency
- COPD or emphysema diagnosed at a younger ageOften before age 45, though this is a general pattern, not a strict cutoff
- Emphysema without a significant smoking history
- Unexplained chronic liver disease, at any age
- Certain patterns of bronchiectasis without another clear explanation
- Ancestry from populations with a higher carrier frequency of AATD-associated gene variantsWorth mentioning to your physician, though testing guidance generally isn't limited to any one ancestry
Why Alpha-1 Antitrypsin Deficiency Matters
Lung Function
Reduced protection from ongoing enzymatic damage typically leads to emphysema, which can progress at a faster rate than typical emphysema, particularly in people who smoke.
Liver Health
In genotypes associated with abnormal protein accumulation in liver cells, some individuals develop liver inflammation, scarring, or, over time, more advanced liver disease, though this is genuinely genotype-dependent and not universal.
Exacerbation and Infection Risk
As with other forms of emphysema, reduced lung reserve can mean recurrent respiratory infections and acute flare-ups have a more significant impact.
Impact on Family Members
Because AATD is inherited, a confirmed diagnosis in one person carries implications for parents, siblings, and children, who may benefit from discussing testing with their own physician.
When Should I Talk to a Pulmonary Specialist?
- COPD or emphysema diagnosed at a younger age than typical
- Emphysema without a strong smoking history
- A family history of alpha-1 antitrypsin deficiency
- Unexplained liver disease, at any age
- Certain patterns of bronchiectasis without another clear cause
- A sibling, parent, or child with a confirmed AATD diagnosis
What Is Alpha-1 Antitrypsin Deficiency?
Alpha-1 antitrypsin deficiency, often abbreviated AATD, is an inherited condition in which the body doesn’t produce enough of, or produces a dysfunctional form of, a protein called alpha-1 antitrypsin. AATD is caused by inherited variants in the gene responsible for producing this protein, and the specific combination of variants a person carries meaningfully affects both their risk and the pattern of disease they may develop.
What Alpha-1 Antitrypsin Normally Does
This protein is made mostly in the liver and released into the bloodstream, where it travels to the lungs and other tissues. It neutralizes a naturally occurring enzyme released by immune cells during ordinary immune activity, keeping that enzyme from damaging healthy tissue in the process.
What Goes Wrong in AATD
When alpha-1 antitrypsin is reduced in amount, doesn’t function properly, or both, that protective balance is lost. The enzyme it would normally neutralize is left comparatively unchecked, and over years, this can gradually damage the elastic tissue of the lungs.
How AATD Leads to Emphysema
The lung-related consequence of alpha-1 antitrypsin deficiency is typically emphysema, damage to the walls of the tiny air sacs deep in the lungs where oxygen and carbon dioxide are exchanged with the blood.
How the Damage Happens
As those walls break down under sustained, unchecked enzymatic activity, the air sacs lose their normal elastic recoil and can merge into larger, less efficient spaces, reducing the lungs’ surface area for gas exchange.
What Makes AATD-Related Emphysema Different
It often develops at a younger age, sometimes appearing in a person’s 30s or 40s, and it can occur with little or no significant smoking history at all. That combination is precisely why AATD deserves specific consideration rather than being dismissed as an unusual case of typical emphysema.
Not everyone who carries an AATD-associated gene variant develops significant lung disease, and the degree of risk varies with the specific genotype involved. Smoking meaningfully compounds this risk, discussed further below.
Liver Involvement: A Genotype-Dependent Concern
Beyond the lungs, alpha-1 antitrypsin deficiency can also affect the liver, though this is genuinely genotype-dependent rather than a universal feature of the condition.
How Liver Involvement Happens
In certain genotypes, the abnormal protein isn’t released normally from the liver cells that produce it. Instead, it accumulates within those cells, and over time, this accumulation can contribute to liver inflammation, scarring, or, in a subset of individuals, more advanced liver disease.
Why It's Not Universal
Not every AATD genotype carries this liver risk, and among those that do, not everyone who carries the genotype goes on to develop significant liver disease. This is part of why genotype or phenotype characterization, discussed below, is a meaningful part of a complete evaluation rather than a purely academic exercise.
Who Should Be Tested
Alpha-1 antitrypsin deficiency is widely recognized as an under-diagnosed and under-recognized condition, in part because its lung-related presentation can resemble typical COPD or emphysema unless a physician specifically considers it. Current testing guidelines generally recommend at least one-time testing for anyone diagnosed with COPD, not only those with an obviously atypical presentation.
Several specific patterns, summarized above, should prompt testing with particular urgency. Any one of these on its own is a reasonable trigger for testing, and a physician can help determine whether it applies to your particular situation.
How AATD Is Diagnosed
A blood test measuring the level of alpha-1 antitrypsin protein in the blood is typically the first step in evaluation. A low level raises suspicion for the condition and generally prompts further characterization.
Confirming and Characterizing AATD
- 01Blood TestMeasures the level of alpha-1 antitrypsin protein in the blood; typically the first step in evaluation.
- 02Low Level IdentifiedA low result raises suspicion for the condition and generally prompts further characterization.
- 03Genetic or Protein-Variant TestingGenetic testing looks directly at the gene variants carried; protein-variant (phenotype) analysis characterizes the specific forms of the protein present.
- 04Variant IdentificationTogether, these tests identify exactly which variant or combination of variants a person has.
- 05Physician InterpretationA physician guides interpretation, since different genotypes carry meaningfully different implications for lung risk, liver risk, and management.
Family Implications
Because alpha-1 antitrypsin deficiency is inherited, a confirmed diagnosis in one person carries real implications for their blood relatives. Parents, siblings, and children may carry the same or a related gene variant, even if they have no current symptoms, so it’s generally worth discussing the diagnosis with close relatives and encouraging them to raise the topic of testing with their own physician.
Smoking Avoidance: Especially Critical
For anyone with alpha-1 antitrypsin deficiency, avoiding smoking, and stopping if currently smoking, carries outsized importance. Smoking introduces additional oxidative stress and further enzyme activity into lungs that are already less protected than normal, and it’s understood to dramatically accelerate the rate of lung damage in people with AATD compared with people who have typical, non-genetic emphysema.
Pulmonary Monitoring
For patients with confirmed AATD-related lung involvement, periodic pulmonary function testing is a standard part of ongoing care, tracking lung function over time to help a physician gauge the pace of any change. The frequency of monitoring is individualized based on a person’s specific situation rather than following one fixed schedule for everyone.
Augmentation Therapy
For certain patients with AATD-related lung disease, intravenous augmentation therapy is an available treatment approach. In general terms, this therapy involves replacing the deficient alpha-1 antitrypsin protein, aiming to help restore some of the lung’s normal protective capacity. Eligibility and the decision to pursue this therapy depend on a person’s specific clinical picture and testing results, and are determined through direct specialist evaluation rather than a general overview like this one.
Specialist Evaluation
A confirmed diagnosis of alpha-1 antitrypsin deficiency generally warrants referral to a pulmonologist for ongoing lung-related evaluation and management. When there’s evidence of liver involvement, whether from abnormal liver blood tests or a genotype known to carry liver risk, referral to a hepatologist for parallel evaluation and follow-up is an important complement to pulmonary care, rather than an either-or choice between the two specialties.
Getting Evaluated
VitalAir Sleep & Lung Center, based in Frisco, Texas and serving patients across the North Dallas–Fort Worth area, evaluates patients with suspected or confirmed alpha-1 antitrypsin deficiency through a full clinical history, pulmonary function testing, and coordination of the blood and genetic testing needed to confirm a diagnosis and characterize the specific variant involved.
What a local evaluation adds is a personalized assessment of your own lung function, genotype, and overall clinical picture, forming the basis for a management plan matched specifically to you.
If you’ve been diagnosed with COPD or emphysema at a younger age, have emphysema without a significant smoking history, have a family history of AATD, or have unexplained liver disease, a conversation with a physician about AATD testing is a reasonable next step.
Patient Questions
What is alpha-1 antitrypsin deficiency?
It's an inherited condition in which the body doesn't produce enough of, or produces a dysfunctional form of, a protein called alpha-1 antitrypsin that normally protects lung tissue from everyday damage. Reduced protection can lead to emphysema and, in some genotypes, to liver disease.
How is AATD different from typical emphysema?
AATD-related emphysema often develops at a younger age, sometimes in a person's 30s or 40s, and can occur with little or no significant smoking history. Typical emphysema is more commonly associated with a longer smoking history and later onset.
Should everyone with COPD be tested for AATD?
Current testing guidelines generally recommend at least one-time testing for anyone diagnosed with COPD, reflecting how often AATD is under-recognized, not only patients with an obviously atypical presentation.
Does AATD always cause liver disease?
No. Liver involvement is genuinely genotype-dependent. Certain genotypes are associated with abnormal protein accumulation in liver cells and a higher risk of liver disease, while others are not, and even among higher-risk genotypes, not everyone develops significant liver disease.
What does AATD testing involve?
A blood test measuring alpha-1 antitrypsin protein level is typically the first step. If that level is low, testing can extend to genetic (genotype) or protein-variant (phenotype) analysis to characterize the specific variant a person carries.
Why does my specific genotype matter?
Different gene variant combinations carry different levels of risk for lung disease and liver disease. Knowing the specific genotype helps a physician understand what to monitor and how to individualize management.
If I'm diagnosed with AATD, should my family members be tested?
Since AATD is inherited, a confirmed diagnosis has implications for blood relatives. Parents, siblings, and children may carry the same or a related gene variant and may wish to discuss testing with their own physician.
Is smoking more dangerous for someone with AATD?
Yes, significantly. Smoking dramatically accelerates lung damage in people with AATD compared with people who have typical emphysema, making smoking avoidance especially critical for anyone with the condition.
What is augmentation therapy?
Augmentation therapy is an intravenous treatment that replaces the deficient alpha-1 antitrypsin protein. It's an available treatment approach for certain patients with AATD-related lung disease, with eligibility determined through specialist evaluation.
Do I need to see both a pulmonologist and a liver specialist?
A pulmonologist is generally involved for ongoing lung-related care. When there's evidence of liver involvement, whether from abnormal liver testing or a genotype known to carry liver risk, a hepatologist is typically involved as well, alongside pulmonary care rather than instead of it.
Can AATD be diagnosed in someone who has never smoked?
Yes. AATD-related emphysema can occur with little or no significant smoking history, and emphysema in a never-smoker is itself one of the patterns that should prompt AATD testing.
Sources
Guidelines and Professional Societies
- Alpha-1 Foundation, a patient advocacy and research organization dedicated to alpha-1 antitrypsin deficiency. Diagnosis and Management of Alpha-1 Antitrypsin Deficiency Clinical Practice Guidelines.View source
- American Thoracic Society and European Respiratory Society. Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency.View source
- American Thoracic Society. Patient Education Information Series, Alpha-1 Antitrypsin Deficiency.View source
Government and Regulatory Sources
- National Heart, Lung, and Blood Institute. Alpha-1 Antitrypsin Deficiency.View source